Diabetes Mellitus Type 2 as a Risk Factor and Outcome Modifier for Cryptococcosis in HIV Negative, Non-transplant Patients, a Propensity Score Match Analysis

Please use this identifier to cite or link to this item: http://hdl.handle.net/10045/138186
Información del item - Informació de l'item - Item information
Title: Diabetes Mellitus Type 2 as a Risk Factor and Outcome Modifier for Cryptococcosis in HIV Negative, Non-transplant Patients, a Propensity Score Match Analysis
Authors: Kung, Vanessa M. | Ferraz, Carolina | Kennis, Matthew | Franco-Paredes, Carlos | Tuells, José | Vargas Barahona, Lilian | Shapiro, Leland | Thompson III, George R. | Chastain, Daniel B. | Henao-Martinez, Andres F.
Research Group/s: Salud Comunitaria (SALUD)
Center, Department or Service: Universidad de Alicante. Departamento de Enfermería Comunitaria, Medicina Preventiva y Salud Pública e Historia de la Ciencia
Keywords: Cryptococcosis | Cryptococcus neoformans | Cryptococcus gattii | Type 2 diabetes mellitus | HIV-negative patients | Non-transplant patients
Issue Date: 31-Oct-2023
Publisher: Springer Nature
Citation: Current Microbiology. 2023, 80:396. https://doi.org/10.1007/s00284-023-03512-9
Abstract: Cryptococcosis is an opportunistic fungal infection of worldwide distribution with significant associated morbidity and mortality. HIV, organ transplantation, malignancy, cirrhosis, sarcoidosis, and immunosuppressive medications are established risk factors for cryptococcosis. Type 2 diabetes mellitus (DM2) has been hypothesized as a risk factor and an outcome modifier for cryptococcosis. We aimed to compare outcomes among HIV-negative, non-transplant (NHNT) patients with and without DM2. We queried a global research network to identify NHNT patients (n = 3280). We performed a propensity score-matched (PSM) analysis comparing clinical outcomes among cryptococcosis patients by DM status. We also characterize adults with cryptococcosis and DM2 as the only risk factor. After PSM, NHNT patients with DM2 were more likely to develop cognitive dysfunction [9% vs. 6%, OR 1.6; 95% CI (1.1–2.3); P = 0.01] but had similar mortality, hospitalization, ICU, and stroke risk after acquiring cryptococcosis when compared to NHNT patients without DM2. Pulmonary cryptococcosis was the most common site of infection. Among 44 cryptococcosis patients with DM2 as the only identifiable risk factor for disease, the annual incidence of cryptococcosis was 0.001%, with a prevalence of 0.002%. DM2 is associated with increased cognitive dysfunction risk in NHNT patients with cryptococcosis. It is rare for DM2 to be the only identified risk factor for developing cryptococcosis. Kidney disease, hyperglycemia, and immune dysfunction can increase the risk of cryptococcosis in patients with DM2.
URI: http://hdl.handle.net/10045/138186
ISSN: 0343-8651 (Print) | 1432-0991 (Online)
DOI: 10.1007/s00284-023-03512-9
Language: eng
Type: info:eu-repo/semantics/article
Rights: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023
Peer Review: si
Publisher version: https://doi.org/10.1007/s00284-023-03512-9
Appears in Collections:INV - SALUD - Artículos de Revistas

Files in This Item:
Files in This Item:
File Description SizeFormat 
ThumbnailKung_etal_2023_CurrMicrobiol_final.pdfVersión final (acceso restringido)631,75 kBAdobe PDFOpen Preview
ThumbnailKung_etal_2023_CurrMicrobiol_preprint.pdfPreprint (acceso abierto)503,77 kBAdobe PDFOpen Preview


Items in RUA are protected by copyright, with all rights reserved, unless otherwise indicated.